Reference Detail

Ref Type
PMID
Authors M Ciomei, E Ardini, L Gianellini, G Borleri, GT Romero, R Ceruti, W Pastori, N Avanzi, D Casero, P Gnocchi, AL Borgia, F Lussana, A Rambaldi, A Galvani, A Isacchi
Title NMS-P088, a novel FLT3, KIT and CSF1R inhibitor, is a promising clinical candidate for AML and CMML treatment.
Journal Proceedings of the American Association for Cancer Research
Vol
Issue
Date
URL https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf
Abstract Text Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
NMS-P088 NMS-P088 1 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
NMS-P088 NMS-P088 inhibits Flt3, Kit, and Csf1r, thus may have anti-tumor activity in hematological cancers (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CSF1R positive chronic myelomonocytic leukemia predicted - sensitive NMS-P088 Preclinical - Patient cell culture Actionable In a preclinical study, NMS-P088 inhibited proliferation of Csf1r-expressing blasts derived from chronic myelomonocytic leukemia patients (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324). detail...